CAR T-Cell Therapy: Revolutionizing Cancer Treatment

September 30, 2020

Ready your research for success with expert insight from TD2 on how to launch a successful CAR-T trial. Learn the key areas to take into account when beginning this type of oncology trial to ensure proper trial preclinical study design, uncover efficiencies and identify toxicity.

Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know

The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...

Read more +

Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus

In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...

Read more +

The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know

Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.